Women's perspective on the COVID-19 pandemic: Walking into a post-peak phase

Sabatino, Jolanda; Moscatelli, Sara; Rustamova, Yasmin; Kotlar, Irina; Avesani, Martina; Brida, Margarita; Gök, Gülay; Borrelli, Nunzia; Marchenko, Oksana; Calvieri, Camilla; Czerwińska-Jelonkiewicz, Katarzyna; Moharem-Elgamal, Sarah; Grapsa, Julia; Öz, Tuğba Kemaloğlu

doi:10.1016/j.ijcard.2020.08.025

Cited by 8 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, analysis of long-term consequences of SARS-CoV-2’s impact on the body of children and adults is ongoing. Approximately 20–55% of patients in young and middle age with COVID-19 were hospitalized, and up to 18.5% of them had a severe course of the disease [ 132 ], wherein patients with cordial and vessels pathology, especially children, including children with congenital pathology, take special place [ 43 , 132 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Heart Lesions in Children: Clinical, Diagnostic and Immunological Changes

Васичкина

Alekseeva

Kudryavtsev

et al. 2023

IJMS

View full text Add to dashboard Cite

In the beginning of COVID-19, the proportion of confirmed cases in the pediatric population was relatively small and there was an opinion that children often had a mild or asymptomatic course of infection. Our understanding of the immune response, diagnosis and treatment of COVID-19 is highly oriented towards the adult population. At the same time, despite the fact that COVID-19 in children usually occurs in a mild form, there is an incomplete understanding of the course as an acute infection and its subsequent manifestations such as Long-COVID-19 or Post-COVID-19, PASC in the pediatric population, correlations with comorbidities and immunological changes. In mild COVID-19 in childhood, some authors explain the absence of population decreasing T and B lymphocytes. Regardless of the patient’s condition, they can have the second phase, related to the exacerbation of inflammation in the heart tissue even if the viral infection was completely eliminated—post infectious myocarditis. Mechanism of myocardial dysfunction development in MIS-C are not fully understood. It is known that various immunocompetent cells, including both resident inflammatory cells of peripheral tissues (for example macrophages, dendritic cells, resident memory T-lymphocytes and so on) and also circulating in the peripheral blood immune cells play an important role in the immunopathogenesis of myocarditis. It is expected that hyperproduction of interferons and the enhanced cytokine response of T cells 1 and 2 types contribute to dysfunction of the myocardium. However, the role of Th1 in the pathogenesis of myocarditis remains highly controversial. At the same time, the clinical manifestations and mechanisms of damage, including the heart, both against the background and after COVID-19, in children differ from adults. Further studies are needed to evaluate whether transient or persistent cardiac complications are associated with long-term adverse cardiac events.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 Heart Lesions in Children: Clinical, Diagnostic and Immunological Changes

Васичкина

Alekseeva

Kudryavtsev

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The presence of pre-existing cardiovascular disease is associated with worse prognosis and increased mortality in COVID-19 patients ( 9 , 11 , 12 ). COVID-19 can result in cardiac and vascular complications including acute cardiac injury, myocardial injury, arrhythmia and venous thromboembolism ( 12 , 13 ). A growing concern over the potential drug-disease interactions in patients with cardiovascular diseases and COVID-19 remains to be solved ( 14 , 15 ).…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally and rapidly developed into a worldwide pandemic. The sudden outburst and rapid dissemination of SARS-CoV-2, with overwhelming public health and economic burdens, highlight an urgent need to develop effective strategies for the diagnosis and treatment of infected patients. In this review, we focus on the current advances in the diagnostics and treatment for SARS-CoV-2 infection. Notably, we also summarize some antineoplastic drugs repurposed for COVID-19 treatment and address the diagnostic and therapeutic challenges for oncologists to manage cancer patients in this COVID-19 era. In addition, we emphasize the importance of organoid technology as a valuable experimental virology platform to better understand the pathogenesis of COVID-19 and assist rapid screening of drugs against COVID-19.

show abstract

“…

…”

mentioning

confidence: 99%

“…Although initially believed to be a respiratory syndrome characterized solely by acute lung injury and respiratory failure, this infectious pathology commonly and adversely affects cardiovascular system. Cardiac injury in COVID-19 patients can be triggered by a multitude of causes, including direct cytopathic damage of cardiomyocytes and indirect injury secondary to systemic inflammation, endothelial activation, and microvascular thrombosis [ [1] , [2] , [3] , [4] , [5] , [6] ]. In addition, the risk of coronary thrombosis due to atherosclerotic plaque rupture/erosion appears to increase during SARS-CoV-2 infection [ 1 , [4] , [5] , [6] , [7] ].…”

mentioning

confidence: 99%

Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter

Gragnano

Cesaro

Pelliccia

et al. 2021

International Journal of Cardiology

View full text Add to dashboard Cite

More than a year after its emergence in Wuhan (China), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has reached a global pandemic status and changed the collective perception of medicine and society permanently [1][2][3][4]. At the time of this writing, the global death toll from coronavirus disease-19 (COVID-19) has exceeded 4 million as SARS-CoV-2 infections crossed 185 million cases worldwide. Although initially believed to be a respiratory syndrome characterized solely by acute lung injury and respiratory failure, this infectious pathology commonly and adversely affects cardiovascular system. Cardiac injury in COVID-19 patients can be triggered by a multitude of causes, including direct cytopathic damage of cardiomyocytes and indirect injury secondary to systemic inflammation, endothelial activation, and microvascular thrombosis [1-6]. In addition, the risk of coronary thrombosis due to atherosclerotic plaque rupture/erosion appears to increase during SARS-CoV-2 infection [1,[4][5][6][7].Nearly two-thirds of patients hospitalized for COVID-19 have evidence of cardiac injury, which has been reported to be associated with more severe illness, greater need for intensive care, and worse prognosis [1,[8][9][10][11]. Previous studies have mainly examined myocardial injury based on abnormal laboratory findings (i.e., rise and/or fall of cardiac troponin on admission or during hospitalization), offering limited evidence on the prevalence and implications of concomitant structural or functional cardiac abnormalities at electrocardiographic and imaging analysis [9,12]. Yet, whether elevated circulating levels of myocardial necrosis biomarkers "in isolation" confers a higher risk of adverse events remains controversial. Giustino et al. recently reported that COVID-19 patients with increased cardiac troponins more frequently have electrocardiographic and echocardiographic abnormalities than those with normal troponin values [8]. They showed that serum troponin elevation was independently associated with an increased risk of in-hospital mortality, but interestingly this effect was confined to patients with

show abstract

Women's perspective on the COVID-19 pandemic: Walking into a post-peak phase

Cited by 8 publications

References 40 publications

COVID-19 Heart Lesions in Children: Clinical, Diagnostic and Immunological Changes

COVID-19 Heart Lesions in Children: Clinical, Diagnostic and Immunological Changes

COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management

Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter

Contact Info

Product

Resources

About